Clinical Trial Update: 64Cu-SAR-bisPSMA Positron Emission Tomography of Patients With Known or Suspected Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for 64Cu-SAR-bisPSMA PET imaging in prostate cancer across Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• 64Cu-SAR-bisPSMA (Copper-64-labeled SAR-bisPSMA)

Snippet

Sponsor: Luke Nordquist, MD | Conditions: Prostate Cancer | Phase 1, Phase 2 | Status: UNKNOWN